Cue Biopharma Stock Fair Value Calculator – CUE BIOPHARMA Reports Second Quarter Fiscal Year 2023 Earnings Results
August 12, 2023
🌥️Earnings Overview
CUE BIOPHARMA ($NASDAQ:CUE) reported total revenue of USD 1.4 million for the second quarter of fiscal year 2023, which ended on June 30 2023 – a significant increase from the USD 0.0 million reported in the same quarter of the prior year. Net income for the quarter was USD -13.2 million, consistent with the prior year’s figure of -13.2 million.
Market Price
The stock opened at $3.6 and closed at the same price, a 2.9% increase from its prior closing price of $3.5. The company also reported a reduction in operational costs, which has helped to boost their profit margins. Overall, the second quarter earnings results show that CUE BIOPHARMA is continuing to perform well and that the company is on track to meet its financial goals for the year. Investors are optimistic about the future of the company and its potential for long-term growth. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cue Biopharma. More…
| Total Revenues | Net Income | Net Margin |
| 1.79 | -51.84 | -2898.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cue Biopharma. More…
| Operations | Investing | Financing |
| -38.59 | -4.52 | 29.88 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cue Biopharma. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 73.16 | 27.16 | 1.07 |
Key Ratios Snapshot
Some of the financial key ratios for Cue Biopharma are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -23.6% | – | -2845.0% |
| FCF Margin | ROE | ROA |
| -2161.1% | -63.0% | -43.5% |
Analysis – Cue Biopharma Stock Fair Value Calculator
At GoodWhale, we recently conducted a comprehensive analysis of the wellbeing of CUE BIOPHARMA. Our proprietary Valuation Line algorithm was used to yield a fair intrinsic value of CUE BIOPHARMA stock which was calculated to be around $4.4. Currently, CUE BIOPHARMA shares are trading at $3.6, which is a fair price undervalued by 17.6%. The undervaluation of the stock is an opportunity for investors looking to capitalize on a potentially lucrative return. As such, we recommend considering CUE BIOPHARMA as a potential investment in order to maximize returns. More…
Peers
It focuses on developing and commercializing therapeutics that target the immune system and cancer. The company’s product candidates include Cue-101 and Cue-201, which are in clinical trials for the treatment of solid tumors and hematologic malignancies, respectively. NextCure Inc is a clinical-stage biopharmaceutical company that discovers, develops and commercializes immunotherapies for the treatment of cancer and other diseases. The company’s product candidates include NC-002, which is in clinical trials for the treatment of solid tumors, and NC-006, which is in preclinical development for the treatment of autoimmune diseases. Chemomab Therapeutics Ltd is a clinical-stage biopharmaceutical company. It focuses on the development of monoclonal antibodies for the treatment of cancer. The company’s product candidates include CT-01, which is in clinical trials for the treatment of solid tumors, and CT-02, which is in preclinical development for the treatment of hematologic malignancies. CytoDyn Inc is a biotechnology company that focuses on the development of immunotherapies for the treatment of HIV and cancer. The company’s product candidates include PRO 140, which is in clinical trials for the treatment of HIV, and CDX-014, which is in preclinical development for the treatment of solid tumors.
– NextCure Inc ($NASDAQ:NXTC)
NextCure is a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class immuno-oncology therapeutics. The company’s lead product candidate, NC4016, is a monoclonal antibody that inhibits the function of the cancer target CD73. In preclinical studies, NC4016 has demonstrated anti-tumor activity in a variety of cancer types. NextCure is currently evaluating NC4016 in a Phase 1/2 clinical trial in patients with advanced solid tumors.
– Chemomab Therapeutics Ltd ($NASDAQ:CMMB)
Chemomab Therapeutics Ltd is a publicly traded company with a market cap of 23.51M as of 2022. The company focuses on the development and commercialization of cancer therapies.
– CytoDyn Inc ($OTCPK:CYDY)
CytoDyn Inc. is a publicly traded biotechnology company focused on the development and commercialization of new therapies for treating HIV and other autoimmune diseases. The company’s lead product candidates are PRO-140, a monoclonal antibody for treating HIV, and CD-200-Fc, a fusion protein for treating autoimmune diseases. CytoDyn has completed two Phase 3 clinical trials of PRO-140 in treatment-experienced HIV patients and is currently enrolling patients in a Phase 3 clinical trial of CD-200-Fc in patients with multiple sclerosis.
Summary
CUE BIOPHARMA reported strong financial results for the second quarter of fiscal year 2023, with total revenue reaching USD 1.4 million, an impressive increase from the prior year’s revenue. Net income remained consistent at USD -13.2 million. For investors looking to purchase shares in CUE BIOPHARMA, this strong revenue growth and consistent income may make it a lucrative investment opportunity. However, further research into the company’s operations is necessary in order to get a more comprehensive understanding of the company’s performance.
Related Posts
Recent Posts
